By investigating the role of the proteins TBX2 and KDM1A in breast cancer, Dr Mullan’s team aims to reveal which patients are likely to fail to respond to current chemotherapy treatments and provide an opportunity for the development of new targeted treatments, including treatments for triple negative breast cancers.
Dr Fiona Kennedy will investigate the feasibility of an online resource to offer support to secondary breast cancer patients and help them to manage their symptoms with the ultimate aim of improving their overall quality of life.
Professor Nicholas Turner and Dr Alicia Okines will lead a clinical trial of the drug crizotinib for patients with lobular breast cancer that has spread to other parts of the body. This trial, called the ROLO study, could lead to a much-needed new treatment for this type of breast cancer.
Dr Boyne will investigate whether the increased risk of secondary breast cancer in patients with type-two diabetes is caused by ‘molecular messages’ carried in fragments of blood cells known as platelets.
When breast cancer spreads it becomes incurable, and can cause debilitating side-effects. Professor Nicola Sibson hopes to find better treatment combinations to control secondary breast tumours in the brain, to improve the quality of life and chances of survival for patients.
Dr Georgia Mavria is studying how a molecule called DOCK4 is involved in the spread of breast cancer to the brain. Her work could lead to new ways to prevent secondary tumours from growing in the brain and ultimately save lives.